Agilent Technologies has unveiled its new ProteoAnalyzer system, alongside updates to existing products, at the Singapore Cell and Gene Therapy Pan Asia Summit (SCGT). This innovative protein analysis platform, featuring automated parallel capillary electrophoresis (CE), delivers rapid, high-resolution analysis while using minimal sample amounts. The ProteoAnalyzer enables researchers to investigate complex protein mixtures, accelerating advancements in the pharmaceutical, biopharmaceutical, and bioengineered food ingredient sectors.
Carsten Thomsen, Associate Vice President of APAC Sales for the Diagnostics and Genomics Group at Agilent, said, "We are thrilled to launch the ProteoAnalyzer, which features all the cutting-edge technologies of the biomolecular platform – elevating translational research from compound to novel applications. Building on the success of Agilent's CE capabilities, the ProteoAnalyzer prioritizes what researchers value most: enabling breakthrough discoveries that improve the quality of life".
Pharma and biopharma companies increasingly use CE solutions to enhance the development of proteins with potential therapeutic interest. To support this, Agilent's ProteoAnalyzer includes easy-to-use QC workflows for assessing the size and purity of proteins such as antibodies and enzymes, and other proteins of interest.
At the SCGT, Agilent Technologies not only introduced the ProteoAnalyzer but also announced updates to its Flow Cytometer product line. The company unveiled the new NovoCyte Opteon, equipped with up to 5 lasers and 73 detectors, aimed at revolutionizing cell analysis research.
For 25 years, Agilent has been assisting clinical labs in providing safe and effective solutions to real-world health challenges across the globe. In the Asia Pacific region, the company collaborates with research institutes such as Singapore's ACTRIS and South Korea's Theragen Bio. These partnerships highlight Agilent's commitment to advancing innovative technology in key areas of medical research.